Sprague Brian L, Stout Natasha K, Schechter Clyde, van Ravesteyn Nicolien T, Cevik Mucahit, Alagoz Oguzhan, Lee Christoph I, van den Broek Jeroen J, Miglioretti Diana L, Mandelblatt Jeanne S, de Koning Harry J, Kerlikowske Karla, Lehman Constance D, Tosteson Anna N A
Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.
Many states have laws requiring mammography facilities to tell women with dense breasts and negative results on screening mammography to discuss supplemental screening tests with their providers. The most readily available supplemental screening method is ultrasonography, but little is known about its effectiveness.
To evaluate the benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Comparative modeling with 3 validated simulation models.
Surveillance, Epidemiology, and End Results Program; Breast Cancer Surveillance Consortium; and medical literature.
Contemporary cohort of women eligible for routine screening.
Lifetime.
Payer.
Supplemental ultrasonography screening for women with dense breasts after a negative screening mammography result.
Breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, biopsies recommended after a false-positive ultrasonography result, and costs.
RESULTS OF BASE-CASE ANALYSIS: Supplemental ultrasonography screening after a negative mammography result for women aged 50 to 74 years with heterogeneously or extremely dense breasts averted 0.36 additional breast cancer deaths (range across models, 0.14 to 0.75), gained 1.7 QALYs (range, 0.9 to 4.7), and resulted in 354 biopsy recommendations after a false-positive ultrasonography result (range, 345 to 421) per 1000 women with dense breasts compared with biennial screening by mammography alone. The cost-effectiveness ratio was $325,000 per QALY gained (range, $112,000 to $766,000). Supplemental ultrasonography screening for only women with extremely dense breasts cost $246,000 per QALY gained (range, $74,000 to $535,000).
The conclusions were not sensitive to ultrasonography performance characteristics, screening frequency, or starting age.
Provider costs for coordinating supplemental ultrasonography were not considered.
Supplemental ultrasonography screening for women with dense breasts would substantially increase costs while producing relatively small benefits.
National Cancer Institute.
许多州都有法律要求乳腺钼靶检查机构告知乳房致密且乳腺钼靶筛查结果为阴性的女性,与她们的医疗服务提供者讨论补充筛查测试。最容易获得的补充筛查方法是超声检查,但其有效性却鲜为人知。
评估对乳房致密女性进行补充超声筛查的益处、危害及成本效益。
采用3个经过验证的模拟模型进行比较建模。
监测、流行病学与最终结果计划;乳腺癌监测联盟;以及医学文献。
符合常规筛查条件的当代女性队列。
终生。
支付方。
对乳腺钼靶筛查结果为阴性的乳房致密女性进行补充超声筛查。
避免的乳腺癌死亡人数、获得的质量调整生命年(QALY)、超声检查结果假阳性后建议进行的活检以及成本。
对于年龄在50至74岁、乳房呈不均匀致密或极度致密的女性,在乳腺钼靶检查结果为阴性后进行补充超声筛查,与仅每两年进行一次乳腺钼靶筛查相比,每1000名乳房致密的女性可额外避免0.36例乳腺癌死亡(各模型范围为0.14至0.75),获得1.7个QALY(范围为0.9至4.7),并在超声检查结果假阳性后导致354例活检建议(范围为345至421)。成本效益比为每获得1个QALY花费325,000美元(范围为112,000至766,000美元)。仅对乳房极度致密的女性进行补充超声筛查,每获得1个QALY花费246,000美元(范围为74,000至535,000美元)。
结论对超声检查性能特征、筛查频率或起始年龄不敏感。
未考虑协调补充超声检查的医疗服务提供者成本。
对乳房致密女性进行补充超声筛查会大幅增加成本,而获益相对较小。
美国国立癌症研究所。